DSP 7238

Drug Profile

DSP 7238

Alternative Names: DSP-7238

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Class Antihyperglycaemics
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 02 Oct 2009 Pharmacokinetics & pharmacodynamics data from in vitro & preclinical trials in Type-2 diabetes mellitus presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD-2009)
  • 09 Jun 2009 Preclinical safety, pharmacokinetics and pharmacodynamics data presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA-2009) (1132718. 1132719)
  • 09 May 2008 Phase-I clinical trials in Type-2 diabetes mellitus in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top